argenx SE at JPMorgan Healthcare Conference Transcript
Great. Good afternoon. I'm James Gordon, JPMorgan European Pharma and Biotech analyst. And today, I've got the pleasure of introducing the Argenx presentation. We're going to have a breakout afterwards in the Sussex room, and I can help lead you there. But with that said, I'll hand over to Tim Van Hauwermeiren for the presentation. Thank you very much.
Thank you, James. Good afternoon, ladies and gentlemen. My promise to you for the next 25 minutes is that we are going to take a close look at our patient focus. We're going to take a look at MyRealWorld MG, our real world evidence study in myasthenia gravis. We're also going to learn how we have been adapting the design of our Phase III global registration trial to the will of the MG patients. We're also going to take a closer look at the late-stage clinical development pipeline of the company.
We're going to take a closer look at efgartigimod and cusatuzumab,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
